Fig. 3
From: Residual cancer is a strong predictor of survival in T3 incidental gallbladder cancer
Five-year OS and DFS for IGC patients with LN/RC (−) and LN/RC ( +) according to the presence of adjuvant chemoradiotherapy. LN/RC (−) lymph node-negative and no residual cancer, LN/RC ( +) lymph node-positive and/or residual cancer; CRT chemoradiotherapy. The 1-, 3-, 5-years OS and DFS for CRT and non-CRT with LN/RC (−) patients are 89% vs 95%, 59% vs 77%, NC vs 50%，and 89% vs 79%, 58% vs 45%, NC vs 37%，respectively; The 1-, 3-, 5-years OS and DFS for CRT and non-CRT with LN/RC (+) patients are 91% vs 67%, 59% vs 12%, NC vs 12%，and 73% vs 31%, 16% vs 12%, NC vs 12%，respectively